To examine the prescribing patterns and outcomes of antithrombotic regimens after venous stent placement.
Methods
A total of 87 patients who received inferior vena cava or iliofemoral venous stents were included in the study. A retrospective review was performed to determine the antithrombotic regimens and the subsequent rates of in-stent restenosis, stent thrombosis, and bleeding.
Results
The prescribing patterns of specific antithrombotic regimens were highly variable. In-stent restenosis and stent thrombosis events were observed in 13 of 63 patients (21%) with available follow-up imaging, while major bleeding events were noted in 6 of 87 patients (7%). Triple therapy appeared to reduce the odds of in-stent restenosis/ stent thrombosis when compared to dual antiplatelet therapy (OR = 0.07, P = 0.01).
Conclusions
Substantial variability exists in antithrombotic therapy following venous stenting at our institution. This study demonstrated a reduction of in-stent restenosis/thrombosis events when utilizing triple therapy compared to antiplatelet-only regimens. However, larger prospective trials are needed to more accurately determine the relative risks and benefits of each antithrombotic regimen.
LangwieserNBernlochnerIWustrowI, et al.
Combination of factor Xa inhibition and antiplatelet therapy after stenting in patients with iliofemoral post-thrombotic venous obstruction.Phlebology2016;
31: 430–437.
3.
MilinisKThaparAShalhoubJ, et al.
Antithrombotic therapy following venous stenting: international Delphi consensus.Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg2018;
55: 537–544.
4.
AbuRahmaAFPerkinsSEWuluJT, et al.
Iliofemoral deep vein thrombosis: conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting.Ann Surg2001;
233: 752–760.
5.
SharifiMMehdipourMBayC, et al.
Endovenous therapy for deep venous thrombosis: the TORPEDO trial.Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv2010;
76: 316–325.
6.
FaxonDPSanbornTAHaudenschildCC.Mechanism of angioplasty and its relation to restenosis.Am J Cardiol1987;
60: 5B–9B.
7.
McBaneRDLeadleyRJBaxiSM, et al.
Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs.Arterioscler Thromb Vasc Biol2008;
28: 413–418.
8.
EijgenraamPCateHTCate-HoekAJ.Venous stenting after deep venous thrombosis and antithrombotic therapy: A systemic review.Rev Vasc Med2014;
2: 88–97.
9.
J. PadrnosLGarciaD.May-Thurner syndrome and thrombosis: a systematic review of antithrombotic use after endovascular stent placement.Res Pract Thromb Haemost2018;
3: 70–78.
10.
Jones WS, Vemulapalli S, Parikh KS, et al. Treatment Strategies for Patients with Lower Extremity Chronic Venous Disease (LECVD). http://www.ncbi.nlm.nih.gov/books/NBK525528/ (2017, accessed 29 November 2019).
11.
Office of the Surgeon General (US) and National Heart, Lung, and Blood Institute (US). The Surgeon General’s call to action to prevent deep vein thrombosis and pulmonary embolism.
Rockville, MD:
Office of the Surgeon General (US), www.ncbi.nlm.nih.gov/books/NBK44178/ (2008, accessed 12 May 2018).
12.
VedanthamSGoldhaberSZJulianJA, et al.
Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis.N Engl J Med2017;
377: 2240–2252.
13.
VedanthemS. Chronic venous thrombosis: relief with adjunctive catheter-directed therapy (The C-TRACT Trial). ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT03250247 (2018, accessed 12 May 2018).
14.
SchulmanSKearonC,
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost JTH2005;
3: 692–694.
15.
MeissnerMH.Indications for platelet aggregation inhibitors after venous stents.Phlebology2013;
28: 91–98.
16.
AngeliniDEElsonPMcCraeK, et al.
Anticoagulant prescription patterns for cancer associated thrombosis: new insights into the use of direct oral anticoagulants. Blood2017;
130: 4725–4725.
17.
FinksSWTrujilloTCDobeshPP.Management of venous thromboembolism: recent advances in oral anticoagulation therapy.Ann Pharmacother2016;
50: 486–501.
18.
SchömigA.Ticagrelor–is there need for a new player in the antiplatelet-therapy field?N Engl J Med2009;
361: 1108–1111.
19.
WallentinLBeckerRCBudajA, et al.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med2009;
361: 1045–1057.
20.
MatetzkySShenkmanBGuettaV, et al.
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.Circulation2004;
109: 3171–3175.
21.
TantryUSBlidenKP, andGurbelPA.Resistance to antiplatelet drugs: current status and future research.Expert Opin Pharmacother2005;
6: 2027–2045.
22.
LevineGNBatesERBittlJA, et al.
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Thorac Cardiovasc Surg2016;
152: 1243–1275.
23.
KearonCAklEAOrnelasJ, et al.
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest2016;
149: 315–352.
24.
HansenMLSørensenRClausenMT, et al.
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.Arch Intern Med2010;
170: 1433–1441.
25.
SørensenRHansenMLAbildstromSZ, et al.
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.Lancet Lond Engl2009;
374: 1967–1974.
26.
DewildeWJMOirbansTVerheugtFWA, et al.
Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.Lancet Lond Engl2013;
381: 1107–1115.
